First Albany Downgrades Anika Therapeutics
First Albany downgraded Anika Therapeutics (ANIK ) to neutral from buy. On Friday, the company posted 8 cents third-quarter earnings per share on a 52% revenue rise and said OrthoVisc traction in the U.S. market to date has been slower than the company would like.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.